98%
921
2 minutes
20
is deregulated in triple negative breast cancer (TNBC) pointing to be a promising biomarker for breast cancer treatment. Precise level of expression is important in the control of cellular growth and proliferation. Designing of -targeted antidotes to restore its basal level of cellular expression holds an optimistic approach towards anti-cancer treatment. transcription is dominantly controlled by Nuclear Hypersensitive Element III-1 (NHE) upstream of the promoter region possessing G-Quadruplex silencer element (). We have investigated the selective binding-interaction profile of a natural phytophenolic compound Curcumin with native G-quadruplex by conducting an array of biophysical experiments and based Molecular Docking and Molecular Dynamic (MDs) simulation studies. Curcumin possesses immense anti-cancerous properties. We have observed significantly increased stability of -G Quadruplex and thermodynamic spontaneity of Curcumin- GQ binding with negative ΔG value. Transcription of is tightly regulated by a complex mechanism involving promoters, enhancers and multiple transcription factors. We have used Curcumin as a model drug to understand the innate mechanism of controlling deregulated back to its basal expression level. We have checked -expression at transcriptional and translational level and proceeded for Chromatin Immuno-Precipitation assay (ChIP) to study the occupancy level of SP1, Heterogeneous nuclear ribonucleoprotein K (hnRNPK), Nucleoside Diphosphate Kinase 2 (NM23-H2) and Nucleolin at NHE upon Curcumin treatment of MDA-MB-231 cells. We have concluded that Curcumin binding tends to drive the equilibrium towards stable G-quadruplex formation repressing back to its threshold-level. On retrospection of the synergistic effect of upregulated and in cancer, we have also reported a new pathway [axis] through which Curcumin trigger apoptosis in cancer cells.Communicated by Ramaswamy H. Sarma.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/07391102.2021.1940284 | DOI Listing |
Stem Cell Rev Rep
September 2025
Paris Cité University, INSERM UMR-S 970, Paris Cardiovascular Research Centre, Paris, France.
Endothelial Colony-Forming Cells (ECFCs) are recognized as key vasculogenic progenitors in humans and serve as valuable liquid biopsies for diagnosing and studying vascular disorders. In a groundbreaking study, Anceschi et al. present a novel, integrative strategy that combines ECFCs loaded with gold nanorods (AuNRs) to enhance tumor radiosensitization through localized hyperthermia.
View Article and Find Full Text PDFAnn Surg Oncol
September 2025
Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Ann Surg Oncol
September 2025
Department of Surgery, Division of Surgical Oncology, UCLA David Geffen School of Medicine, Los Angeles, CA, USA.
Ann Surg Oncol
September 2025
Department of General Surgery, Abdulkadir Yuksel State Hospital, Gaziantep, Turkey.
Breast Cancer Res Treat
September 2025
Department of Pharmacy, Duke University Hospital, Durham, NC, USA.
Purpose: Limited data is available assessing sequencing of antibody drug conjugates (ADCs) in patients with hormone receptor-positive (HR +), human epidermal growth factor 2 (HER2)-negative, HER2-low, and triple-negative metastatic breast cancer (MBC), including patients with brain metastases (BrM) or leptomeningeal disease (LMD). This study assesses the efficacy and safety of sequential sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) in MBC and impact on chemotherapy (CTX).
Methods: This is a single-center, retrospective, cohort study in adult patients with HR + , HER2-negative, or low MBC who received T-DXd and/or SG.